-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onabotulinumtoxin A in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onabotulinumtoxin A in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onabotulinumtoxin A in Chronic Obstructive Pulmonary Disease (COPD)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onabotulinumtoxin A in Myofascial Pain Syndrome (Chronic Myofascial Pain)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onabotulinumtoxin A in Myofascial Pain Syndrome (Chronic Myofascial Pain) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onabotulinumtoxin A in Myofascial Pain Syndrome (Chronic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Givinostat Hydrochloride in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Givinostat Hydrochloride in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Givinostat Hydrochloride in Duchenne Muscular Dystrophy Drug Details: Givinostat...
-
Sector Analysis
Stretchers and Cots Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Stretchers and Cots Market Report Overview The stretchers and cots market was valued at $1.11 billion in 2023 and is expected to grow at a CAGR of more than 2% during 2023-2033. Stretchers and cots support overall patient care and safety, irrespective of the cause of their hospital visits. They form the equipment base of all healthcare facilities in any country. For any kind of treatment to be successful, the hospital must be equipped with basic supplies such as transport...
-
Sector Analysis
Pulse Oximeter Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Pulse Oximeter Systems Market Report Overview The pulse oximeter systems market size was valued at $1.37 billion in 2023 and will grow at a CAGR of more than 3% during the forecast period 2023 and 2033. Factors such as improved functions and user-friendly design will boost the pulse oximeter system demand. A pulse oximeter system is a photoelectric instrument that measures the oxygen saturation of blood noninvasively and continuously. They are commonly used in the operating room during procedures requiring...
-
Sector Analysis
Arteriotomy Closure Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Arteriotomy Closure Devices Market Report Overview The arteriotomy closure devices market size was $820.9 million in 2023. The market is expected to grow at a CAGR of more than 3% during 2023-2033. Arteriotomy closure devices are used to achieve the hemostasis of an arterial puncture site after an angiography procedure, percutaneous coronary intervention, or a peripheral intervention. Such devices are used to decrease vascular complications and reduce the time required for hemostasis and ambulation compared to traditional methods. Arteriotomy Closure...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Givinostat in Duchenne Muscular Dystrophy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Givinostat in Duchenne Muscular Dystrophy Drug Details: Givinostat is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Givinostat in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Givinostat in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Givinostat in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onabotulinumtoxin A in Essential Tremor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onabotulinumtoxin A in Essential Tremor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onabotulinumtoxin A in Essential Tremor Drug Details: Onabotulinumtoxin A (Botox /...